Poolbeg Pharma PLC Stock

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:29 2024-07-12 am EDT 5-day change 1st Jan Change
13.55 GBX 0.00% Intraday chart for Poolbeg Pharma PLC -1.81% +49.72%
Sales 2024 * - Sales 2025 * - Capitalization 67.75M 87.97M
Net income 2024 * -6M -7.79M Net income 2025 * -6M -7.79M EV / Sales 2024 * -
Net cash position 2024 * 6.2M 8.05M Net cash position 2025 * 500K 649K EV / Sales 2025 * -
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-11.3 x
Employees 15
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.62%
More Fundamentals * Assessed data
Dynamic Chart
1 week-1.81%
Current month+4.23%
1 month-0.73%
3 months+38.27%
6 months+43.39%
Current year+49.72%
More quotes
1 week
13.45
Extreme 13.45
14.04
1 month
12.00
Extreme 12
14.04
Current year
8.02
Extreme 8.015
15.77
1 year
6.38
Extreme 6.38
15.77
3 years
4.00
Extreme 4
15.77
5 years
4.00
Extreme 4
15.77
10 years
4.00
Extreme 4
15.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 21-04-30
Director of Finance/CFO 37 20-12-31
Investor Relations Contact - 20-12-31
Members of the board TitleAgeSince
Director/Board Member 60 -
Chief Executive Officer 53 21-04-30
Founder 59 20-08-31
More insiders
Date Price Change Volume
24-07-12 13.55 0.00% 694,904
24-07-11 13.55 0.00% 1,623,775
24-07-10 13.55 -1.81% 4,381,424
24-07-09 13.8 0.00% 2,965,154
24-07-08 13.8 0.00% 1,752,077

Delayed Quote London S.E., July 12, 2024 at 11:35 am EDT

More quotes
Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1355 GBP
Average target price
0.21 GBP
Spread / Average Target
+54.98%
Consensus

Annual profits - Rate of surprise